The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
Open accessAbstract
BACKGROUND: The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure. METHODS: We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat. FINDINGS: Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/89 mm Hg in participants without previous cardiovascular disease (n=186 988). There was substantial spread in participants' blood pressure at baseline, with 31 239 (19·8%) of participants with previous cardiovascular disease and 14 928 (8·0%) of individuals without previous cardiovascular disease having a systolic blood pressure of less than 130 mm Hg. The relative effects of blood pressure-lowering treatment were proportional to the intensity of systolic blood pressure reduction. After a median 4·15 years' follow-up (Q1-Q3 2·97-4·96), 42 324 participants (12·3%) had at least one major cardiovascular event. In participants without previous cardiovascular disease at baseline, the incidence rate for developing a major cardiovascular event per 1000 person-years was 31·9 (95% CI 31·3-32·5) in the comparator group and 25·9 (25·4-26·4) in the intervention group. In participants with previous cardiovascular disease at baseline, the corresponding rates were 39·7 (95% CI 39·0-40·5) and 36·0 (95% CI 35·3-36·7), in the comparator and intervention groups, respectively. Hazard ratios (HR) associated with a reduction of systolic blood pressure by 5 mm Hg for a major cardiovascular event were 0·91, 95% CI 0·89-0·94 for partipants without previous cardiovascular disease and 0·89, 0·86-0·92, for those with previous cardiovascular disease. In stratified analyses, there was no reliable evidence of heterogeneity of treatment effects on major cardiovascular events by baseline cardiovascular disease status or systolic blood pressure categories. INTERPRETATION: In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high-normal blood pressure values. These findings suggest that a fixed degree of pharmacological blood pressure lowering is similarly effective for primary and secondary prevention of major cardiovascular disease, even at blood pressure levels currently not considered for treatment. Physicians communicating the indication for blood pressure lowering treatment to their patients should emphasise its importance on reducing cardiovascular risk rather than focusing on blood pressure reduction itself. FUNDING: British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A previous study based on patients treated with antihypertensive medications estimated that reducing systolic BP by 5 mmHg led to a 9% risk reduction of cardiovascular diseases [79].”
From Self-measurement of blood pressure at home using a cuff device for change in blood pressure levels: systematic review and meta-analysis (2025) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and lowering BP substantially reduces that risk.5–7”
From International Consensus on Standardized Clinic Blood Pressure Measurement – A Call to Action (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Based on this evidence [79], a reduction in systolic BP of 3.27 mmHg with HBPM might reduce cardiovascular risks by 6.0%, if our results can be applied to the management of hypertensive patients.”
From Self-measurement of blood pressure at home using a cuff device for change in blood pressure levels: systematic review and meta-analysis (2025) · cites this paper as [79]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To date, all major outcome clinical trials that evaluate the efficacy of pharmacotherapy in reducing BP levels have measured office BP levels using the upper-arm-cuff method13.”
From Blood pressure and its variability: classic and novel measurement techniques (2022) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Self-citationA Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationEttehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Self-citationStatistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
A stagewise rejective multiple test procedure based on a modified Bonferroni test
HOMMEL, G. (1988) · Biometrika · doi:10.1093/biomet/75.2.383 · Cited by 1,367
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Cited by
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Self-citationMancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationMartin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Self-citation2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Self-citationMartin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Self-citation
Metadata
- Authors
- Rahimi, K., Bidel, Z., Nazarzadeh, M., Copland, E., Canoy, D., Ramakrishnan, R., Pinho-Gomes, A.-C., Woodward, M., Adler, A., Agodoa, L., Algra, A., Asselbergs, F. W., Beckett, N. S., Berge, E., Black, H., Brouwers, F. P. J., Brown, M., Bulpitt, C. J., Byington, R. P., Cushman, W. C., Cutler, J., Devereaux, R. B., Dwyer, J., Estacio, R., Fagard, R., Fox, K., Fukui, T., Gupta, A. K., Holman, R. R., Imai, Y., Ishii, M., Julius, S., Kanno, Y., Kjeldsen, S. E., Kostis, J., Kuramoto, K., Lanke, J., Lewis, E., Lewis, J. B., Lievre, M., Lindholm, L. H., Lueders, S., MacMahon, S., Mancia, G., Matsuzaki, M., Mehlum, M. H., Nissen, S., Ogawa, H., Ogihara, T., Ohkubo, T., Palmer, C. R., Patel, A., Pfeffer, M. A., Pitt, B., Poulter, N. R., Rakugi, H., Reboldi, G., Reid, C., Remuzzi, G., Ruggenenti, P., Saruta, T., Schrader, J., Schrier, R., Sever, P., Sleight, P., Staessen, J. A., Suzuki, H., Thijs, L., Ueshima, K., Umemoto, S., van Gilst, W. H., Verdecchia, P., Wachtell, K., Whelton, P., Wing, L., Yui, Y., Yusuf, S., Zanchetti, A., Zhang, Z.-Y., Anderson, C., Baigent, C., Brenner, B. M., Collins, R., de Zeeuw, D., Lubsen, J., Malacco, E., Neal, B., Perkovic, V., Rodgers, A., Rothwell, P., Salimi-Khorshidi, G., Sundström, J., Turnbull, F., Viberti, G., Wang, J., Chalmers, J., Teo, K. K., Pepine, C. J., & Davis, B. R.
- ORCID
- Rahimi, Kazem
- Bidel, Zeinab
- Nazarzadeh, Milad
- Copland, Emma
- Canoy, Dexter
- Ramakrishnan, Rema
- Woodward, Mark
- Adler, Amanda
- Algra, Ale
- Asselbergs, Folkert W
- Beckett, Nigel S
- Brouwers, Frank P J
- Brown, Morris
- Cushman, William C
- Dwyer, Jamie
- Fox, Kim
- Fukui, Tsuguya
- Gupta, Ajay K
- Holman, Rury R
- Imai, Yutaka
- Ishii, Masao
- Kanno, Yoshihiko
- Kjeldsen, Sverre E
- Kostis, John
- Lewis, Edmund
- Lewis, Julia B
- Lindholm, Lars H
- MacMahon, Stephen
- Mancia, Giuseppe
- Mehlum, Maria H
- Nissen, Steven
- Ogawa, Hiroshi
- Ogihara, Toshio
- Ohkubo, Takayoshi
- Patel, Anushka
- Pitt, Bertram
- Poulter, Neil R
- Rakugi, Hiromi
- Reboldi, Gianpaolo
- Reid, Christopher
- Remuzzi, Giuseppe
- Ruggenenti, Piero
- Staessen, Jan A
- Suzuki, Hiromichi
- Thijs, Lutgarde
- Umemoto, Seiji
- Verdecchia, Paolo
- Wachtell, Kristian
- Whelton, Paul
- Yusuf, Salim
- Zanchetti, Alberto
- Zhang, Zhen-Yu
- Anderson, Craig
- Baigent, Colin
- Collins, Rory
- Neal, Bruce
- Perkovic, Vlado
- Rodgers, Anthony
- Rothwell, Peter
- Sundström, Johan
- Chalmers, John
- Teo, Koon K
- Pepine, Carl J
- Davis, Barry R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 397
- Issue
- 10285
- Pages
- 1625-1636
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC8102467
- OpenAlex
- W3157857666
- Cited by
- 1,074
- References
- 40
- Citations by year
- 2026: 205 · 2025: 254 · 2024: 215 · 2023: 183 · 2022: 157 · 2021: 58
- FWCI
- 29.93
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-05-22)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Oxford Martin School
- British Heart Foundation
- NIHR Oxford Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- blood pressure reduction, antihypertensive drugs, major cardiovascular events, systolic blood pressure, high-normal blood pressure, primary prevention, secondary prevention, cardiovascular disease, hypertension, heart failure, stroke, myocardial infarction, ischemic heart disease, treatment intensity
- MeSH terms
- Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Heart Failure, Hospitalization, Humans, Hypertension, Myocardial Infarction, Primary Prevention, Proportional Hazards Models, Myocardial Ischemia, Stroke, Secondary Prevention, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00590-0
- The paper
- Rahimi, K., Bidel, Z., Nazarzadeh, M., Copland, E., Canoy, D., Ramakrishnan, R., Pinho-Gomes, A.-C., Woodward, M., Adler, A., Agodoa, L., Algra, A., Asselbergs, F. W., Beckett, N. S., Berge, E., Black, H., Brouwers, F. P. J., Brown, M., Bulpitt, C. J., Byington, R. P., . . . Davis, B. R. (2021). Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(21)00590-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.